LITS

#4418
Lite Strategy, Inc. - Common Stock
0.9 8 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.98
0.98
Intervallo Annuale
0.69
3.23
Variazione giornaliera
-2.00%
Variazione Mensile
-1.01%
Variazione di 6 mesi
-9.26%
Variazione Annuale
-67.11%
Chiusura Precedente
1.0 0
Open
0.9 8
Minimo
0.9 8
Massimo
0.9 8
Volume
2
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, 18 December 2023

Full document

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by MEI Pharma, Inc. on December 18, 2023. The filing details the voting results for four proposals submitted to shareholders. Note: The request metadata references "Lite Strategy, Inc.," but the filing text explicitly identifies the registrant as MEI Pharma, Inc.

Key Financial Metrics

This filing is a Current Report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

At the Annual Meeting, 4,413,238 shares were represented out of 6,662,857 shares outstanding. The following proposals were voted upon:

  • Proposal 1 (Election of Directors): Three directors were elected to three-year terms expiring in 2027:
    • Mr. James Flynn: 2,643,853 For; 24,360 Withheld.
    • Mr. Taheer Datoo: 2,230,727 For; 435,794 Withheld.
    • Mr. Steven Wood: 2,644,765 For; 23,448 Withheld.
  • Proposal 2 (Advisory Vote on Executive Compensation): Approved.
    • For: 2,510,335; Against: 149,459; Abstain: 8,419.
  • Proposal 3 (Frequency of Say-on-Pay): Approved. Shareholders voted to hold an advisory vote on executive compensation annually (1 Year).
    • 1 Year: 2,534,092; 2 Years: 1,870; 3 Years: 102,716; Abstain: 29,535.
  • Proposal 4 (Ratification of Auditors): Approved. BDO USA, P.C. was ratified as the independent auditor for the fiscal year ending June 30, 2024.
    • For: 4,366,180; Against: 24,327; Abstain: 22,731.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly limited to the reporting of stockholder voting outcomes.

Investor Verification Checklist

  • Verify the company name discrepancy between the request metadata ("Lite Strategy, Inc.") and the filing text ("MEI Pharma, Inc.").
  • Confirm the total number of shares outstanding (6,662,857) and the percentage of shares represented at the meeting (approximately 66.2%).
  • Review the definitive proxy statement referenced in the filing for detailed biographical information on the elected directors and executive compensation specifics.
  • Check subsequent filings for the audited financial results for the fiscal year ending June 30, 2024, as BDO USA, P.C. was ratified as the auditor for this period.